BDBM230133 US10106559, Example 65::US10435415, Example 65::US9334290, 64::US9334290, 65::US9850258, Example 65

SMILES Cc1c(cccc1-n1c(=O)cc2c(Cl)cccn2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O

InChI Key

Data  16 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 230133   

TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50:  0.340nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50: >2.00E+3nMAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50: >2.00E+3nMpH: 7.4 T: 2°CAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50: >2.00E+3nMpH: 7.4 T: 2°CAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50:  0.340nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50: >2.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50:  0.460nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50: >2.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50:  0.340nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50: >2.00E+3nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50:  0.460nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50: >2.00E+3nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50:  0.340nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50: >2.00E+3nMAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50:  0.460nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230133(US10106559, Example 65 | US10435415, Example 65 | ...)
Affinity DataIC50:  0.460nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent